TSCAN THERAPEUTICS IN

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

24 Apr 2024 16:05:34 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

24 Apr 2024 11:03:30 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

22 Apr 2024 17:01:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Upsized Public Offering

19 Apr 2024 10:05:23 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

17 Apr 2024 00:30:57 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

16 Apr 2024 16:25:22 By Nasdaq GlobeNewswire

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

16 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

08 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

06 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

14 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

18 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

09 Dec 2023 12:00:00 By Nasdaq GlobeNewswire